India, Oct. 14 -- Femasys Inc. (FEMY), a biomedical company that develops fertility and non-surgical permanent birth control solutions, announced that it has doubled the number of actively enrolling sites in its FINALE pivotal trial evaluating FemBloc to twelve across the United States.
The FINALE pivotal trial is a prospective, multi-centre, open-label, single-arm study evaluating the safety and effectiveness of FemBloc as a non-surgical permanent birth control option.
The expanded network of academic centres and private clinical practices now includes Baylor Research Institute and Columbia University Medical Centre, joining existing academic sites Maimonides Medical Centre, Stanford University, University of California Davis and the Uni...